MiNK Therapeutics Shares Set to Reverse Split on Tuesday, January 28th (NASDAQ:INKT)

MiNK Therapeutics, Inc. (NASDAQ:INKT)’s stock is scheduled to reverse split before the market opens on Tuesday, January 28th. The 1-10 reverse split was announced on Tuesday, January 21st. The number of shares owned by shareholders will be adjusted after the market closes on Monday, January 27th.

MiNK Therapeutics Stock Performance

MiNK Therapeutics stock opened at $0.98 on Friday. MiNK Therapeutics has a twelve month low of $0.46 and a twelve month high of $1.90. The firm has a market cap of $38.64 million, a PE ratio of -2.50 and a beta of 0.10. The firm’s 50 day moving average price is $0.71 and its two-hundred day moving average price is $0.77.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on INKT. Robert W. Baird cut their price target on shares of MiNK Therapeutics from $8.00 to $4.00 and set an “outperform” rating on the stock in a report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of MiNK Therapeutics in a research note on Friday, November 15th.

Institutional Investors Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Renaissance Technologies LLC boosted its stake in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 127,841 shares of the company’s stock after acquiring an additional 22,613 shares during the quarter. Renaissance Technologies LLC owned 0.37% of MiNK Therapeutics worth $121,000 as of its most recent SEC filing. 2.87% of the stock is currently owned by institutional investors.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.